286 related articles for article (PubMed ID: 9678800)
41. Protein C, protein S and antithrombin III levels in the course of bone marrow and subsequent liver transplantation due to veno-occlusive disease.
Salat C; Holler E; Göhring P; Poley S; Kolb HJ; Pihusch R; Reinhardt B; Krämling HJ; Haller M; Hiller E
Eur J Med Res; 1996 Nov; 1(12):571-4. PubMed ID: 9438165
[TBL] [Abstract][Full Text] [Related]
42. Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Castenskiold EC; Kelsey SM; Collins PW; Coldwell RD; Allen PD; Side LE; Makin HL; Goldstone AH; Newland AC
Bone Marrow Transplant; 1995 Jun; 15(6):879-84. PubMed ID: 7581085
[TBL] [Abstract][Full Text] [Related]
43. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM).
Bacigalupo A; Oneto R; Bruno B; Lamparelli T; Gualandi F; Bregante S; Raiola AM; Di Grazia C; Dominietto A; Lombardi A; Frassoni F; Van Lint MT
Bone Marrow Transplant; 2001 Dec; 28(11):1041-5. PubMed ID: 11781614
[TBL] [Abstract][Full Text] [Related]
44. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
45. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
[TBL] [Abstract][Full Text] [Related]
46. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
[TBL] [Abstract][Full Text] [Related]
47. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
[TBL] [Abstract][Full Text] [Related]
48. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
49. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
[TBL] [Abstract][Full Text] [Related]
50. Paediatric allogeneic bone marrow transplantation for homozygous beta-thalassaemia, the Dutch experience.
Ball LM; Lankester AC; Giordano PC; van Weel MH; Harteveld CL; Bredius RG; Smiers FJ; Egeler RM; Vossen JM
Bone Marrow Transplant; 2003 Jun; 31(12):1081-7. PubMed ID: 12796787
[TBL] [Abstract][Full Text] [Related]
51. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation.
Foley R; Couban S; Walker I; Greene K; Chen CS; Messner H; Gauldie J
Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399
[TBL] [Abstract][Full Text] [Related]
52. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
[TBL] [Abstract][Full Text] [Related]
53. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
54. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality.
Robin M; Guardiola P; Dombret H; Baruchel A; Esperou H; Ribaud P; Devergie A; Gluckman E; Socié G
Bone Marrow Transplant; 2003 May; 31(10):877-87. PubMed ID: 12748664
[TBL] [Abstract][Full Text] [Related]
55. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
Jabro G; Koc Y; Boyle T; Schenkein DP; Ravalese J; Wazer D; Miller KB
Biol Blood Marrow Transplant; 1999; 5(3):173-9. PubMed ID: 10392963
[TBL] [Abstract][Full Text] [Related]
56. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
Styler MJ; Crilley P; Biggs J; Moul J; Copelan E; Topolsky D; Avalos B; Penza S; Sabol P; Downs K; Szer J; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Jul; 18(1):171-6. PubMed ID: 8832011
[TBL] [Abstract][Full Text] [Related]
57. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.
Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Callander NS; Clement DJ
Bone Marrow Transplant; 1992 Oct; 10(4):367-72. PubMed ID: 1422493
[TBL] [Abstract][Full Text] [Related]
58. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
Zaretsky Y; Rifkind J; Lockwood G; Tsang R; Kiss T; Hasegawa W; Fyles G; Tejpar I; Loach D; Minden M; Messner H; Lipton JH
Bone Marrow Transplant; 2007 Sep; 40(5):423-30. PubMed ID: 17603516
[TBL] [Abstract][Full Text] [Related]
59. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
60. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
